SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BMY (bristol myers squibb) -- Ignore unavailable to you. Want to Upgrade?


To: DewDiligence_on_SI who wrote (155)10/25/2018 12:40:19 PM
From: Miljenko Zuanic  Respond to of 194
 
Yes, it was not. And, we do not know is Opdivo troubling component, or NKTR-214?
In 2L Opdivo work comfortable well,..so what is wrong for front-line, relative to keytruda?



To: DewDiligence_on_SI who wrote (155)10/25/2018 1:20:25 PM
From: Miljenko Zuanic  Read Replies (2) | Respond to of 194
 
I do not follow MRK!

Have any info on Keytruda + Y (KEYNOTE-598, clinicaltrials.gov ), almost like ex-US P3 trial, 1L NSCLC?